JP2020534012A5 - - Google Patents

Download PDF

Info

Publication number
JP2020534012A5
JP2020534012A5 JP2020516576A JP2020516576A JP2020534012A5 JP 2020534012 A5 JP2020534012 A5 JP 2020534012A5 JP 2020516576 A JP2020516576 A JP 2020516576A JP 2020516576 A JP2020516576 A JP 2020516576A JP 2020534012 A5 JP2020534012 A5 JP 2020534012A5
Authority
JP
Japan
Prior art keywords
seq
variable region
kappa light
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020516576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534012A (ja
JP7295098B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2018/106619 external-priority patent/WO2019057100A1/en
Publication of JP2020534012A publication Critical patent/JP2020534012A/ja
Publication of JP2020534012A5 publication Critical patent/JP2020534012A5/ja
Application granted granted Critical
Publication of JP7295098B2 publication Critical patent/JP7295098B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020516576A 2017-09-21 2018-09-20 新規抗cd19抗体 Active JP7295098B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017102631 2017-09-21
CNPCT/CN2017/102631 2017-09-21
PCT/CN2018/106619 WO2019057100A1 (en) 2017-09-21 2018-09-20 NEW ANTI-CD19 ANTIBODIES

Publications (3)

Publication Number Publication Date
JP2020534012A JP2020534012A (ja) 2020-11-26
JP2020534012A5 true JP2020534012A5 (enExample) 2021-10-28
JP7295098B2 JP7295098B2 (ja) 2023-06-20

Family

ID=65810659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020516576A Active JP7295098B2 (ja) 2017-09-21 2018-09-20 新規抗cd19抗体

Country Status (13)

Country Link
US (1) US11497769B2 (enExample)
EP (1) EP3684820A4 (enExample)
JP (1) JP7295098B2 (enExample)
KR (2) KR20250042189A (enExample)
CN (2) CN115819588A (enExample)
AU (2) AU2018336520B2 (enExample)
BR (1) BR112020005402A2 (enExample)
CA (1) CA3074524A1 (enExample)
IL (2) IL317928A (enExample)
MX (2) MX2020003093A (enExample)
SG (1) SG11202001817PA (enExample)
TW (2) TWI812645B (enExample)
WO (1) WO2019057100A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN110003334B (zh) * 2019-04-12 2023-05-09 深圳普瑞金生物药业股份有限公司 多肽、cd19单域抗体及其制备方法、核苷酸序列及试剂盒
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
CN111303287B (zh) * 2019-12-05 2022-05-20 常州费洛斯药业科技有限公司 一种anti-CD19的全人源抗体或抗体片段及其嵌合抗原受体和应用
CN110922482B (zh) * 2019-12-25 2021-08-31 源道隆(苏州)医学科技有限公司 可结合cd19的多肽及其应用
KR20230005268A (ko) 2020-04-24 2023-01-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-cd19 항체 및 이의 용도
CN111840571B (zh) * 2020-08-03 2022-09-20 杭州皓阳生物技术有限公司 一种抗体药物偶联物及其用途
WO2022266075A1 (en) 2021-06-14 2022-12-22 Caribou Biosciences, Inc. Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
WO2023280297A1 (zh) * 2021-07-09 2023-01-12 江苏先声药业有限公司 Cd19抗体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260731A1 (en) 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
EP2216342B1 (en) * 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
CN101233156B (zh) * 2005-06-20 2012-06-27 米德列斯公司 Cd19抗体及其用途
JP5825756B2 (ja) * 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドXencor、 Inc. Cd19を標的とする最適化抗体
AU2007294575B2 (en) 2006-09-08 2013-06-27 Viela Bio, Inc. Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CL2007003622A1 (es) * 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
DK2211904T3 (en) * 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
SG173654A1 (en) * 2009-02-23 2011-09-29 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to cd19 and their uses
EP2409993A1 (en) * 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) * 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2014065402A1 (ja) * 2012-10-26 2014-05-01 株式会社ペルセウスプロテオミクス 抗ヒトcd40モノクローナル抗体及びその利用
AU2013360335B2 (en) * 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9758575B2 (en) * 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
KR102761077B1 (ko) * 2015-10-02 2025-02-04 에프. 호프만-라 로슈 아게 높은 친화성을 갖는 항-인간 cd19 항체
MX2018015414A (es) 2016-06-30 2019-08-01 Hoffmann La Roche Terapia de célula t adoptiva mejorada.
CA3102562A1 (en) 2018-06-07 2019-12-12 Cullinan Management, Inc. Multi-specific binding proteins and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2020534012A5 (enExample)
JP2013506428A5 (enExample)
JP7257971B2 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
WO2020114478A1 (zh) Cd3抗体及其药物用途
JP2020510422A5 (enExample)
JP2020513791A5 (enExample)
JP2018527919A5 (enExample)
JP2018532383A5 (enExample)
JP2012523848A5 (enExample)
JP2018506961A5 (enExample)
JP2009518039A5 (enExample)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
RU2012112340A (ru) Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
JP2019523651A (ja) 抗psma抗体およびその使用
JP2019523651A5 (enExample)
JP2020534830A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2021510533A (ja) 抗4−1bb抗体、その抗原結合フラグメント、およびその医学的使用
WO2020114479A1 (zh) 多特异性蛋白分子
CN117024592B (zh) 抗b7h3抗体及其用途
JP2019512207A5 (enExample)
IL273389B1 (en) New anti-CD19 antibodies
JP7512413B2 (ja) 抗pd-l1およびpd-l2抗体ならびにその誘導体および用途
JP2024001073A5 (enExample)
JP2014515600A5 (enExample)